Drug intelligence / Profile preview

BIIB-095

Development stage: Phase 1
Lead developer: Biogen
Modality: Small Molecules
Administration: Oral

Overview

BIIB-095 is an oral small molecule drug developed by Biogen for the treatment of chronic pain, particularly neuropathic pain and painful diabetic polyneuropathy. It acts as a selective inhibitor (blocker) of the Nav1.7 voltage-gated sodium channel (Sodium channel protein type IX alpha subunit), a target implicated in the transmission of pain signals in the nervous system. By blocking Nav1.7, BIIB-095 was designed to reduce or prevent pain signaling[1][2][3][4]. The drug reached phase 1 clinical trials but development has since been discontinued[1][2].

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on BIIB-095.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIIB-095.

Explore the full profile